logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10744143 B1

PDFFull Text
Date of Patent:
Aug. 18, 2020

Filed:

Jan. 11, 2019

Therapeutic and method of use

Applicant:

Predictive Therapeutics, Llc, Salt Lake City, UT (US);

Inventor:

Bradley C. Robinson, Salt Lake City, UT (US);

Assignee:

Predictive Therapeutics, LLC, Salt Lake City, UT (US);

Attorney:

Wilson, Sonsini, Goodrich & Rosati

Primary Examiner:

Michael V Meller

Int. Cl.
CPC ...
A61K 36/00 (2006.01); A61K 31/567 (2006.01); A61K 45/06 (2006.01); A61K 31/138 (2006.01); A61K 31/585 (2006.01); A61K 31/12 (2006.01); A61K 31/192 (2006.01); A61K 31/415 (2006.01); A61K 31/536 (2006.01); A61K 31/5415 (2006.01); A61K 31/352 (2006.01); A61K 31/57 (2006.01); A61K 36/185 (2006.01); A61K 38/38 (2006.01);
U.S. Cl.
CPC ...
A61K 31/567 (2013.01); A61K 31/12 (2013.01); A61K 31/138 (2013.01); A61K 31/192 (2013.01); A61K 31/352 (2013.01); A61K 31/415 (2013.01); A61K 31/536 (2013.01); A61K 31/5415 (2013.01); A61K 31/57 (2013.01); A61K 31/585 (2013.01); A61K 36/00 (2013.01); A61K 36/185 (2013.01); A61K 38/385 (2013.01); A61K 45/06 (2013.01);
Abstract

The present invention is a compound comprising an anti-inflammatory drug component consisting preferably of at least one of an NSAID portion and aportion and at least one of a progestin component and a progesterone component. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased risk—especially genetically determined risk—of developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.

Find Patent Forward Citations

Loading…